Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plerixafor and G-CSF conditioning in CGD
NCT03547830Phase 2Unknown
- Sponsor
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
- Start
- Apr 2019
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of plerixafor in chronic granulomatous disease (CGD), sponsored by Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Primary endpoint: Event free survival at 1 year. Status: unknown.
02
Drugs
plerixafor
03
Conditions
chronic granulomatous disease (CGD)
Beyond the preview
Go deeper on NCT03547830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03547830.